Renata launches new products in UK

Renata PLC, one of the leading publicly listed drug makers, has launched a new product —Hydrocortisone 5 mg Tablets — in the United Kingdom (UK) market.

The new products will be commercialised under the livery of Renata (UK) Limited, according to a disclosure published on the stock exchanges website yesterday (24 November). 

Hydrocortisone is an essential corticosteroid indicated for replacement therapy in patients with adrenocortical insufficiency, and the 5 mg strength offers clinicians greater flexibility in titrating doses to mimic physiological cortisol levels, thereby supporting more precise patient management.

The product is manufactured at Renata's UK MHRA-approved, European Union Good Manufacturing Practice (EU GMP)-certified potent facility in Mirpur, the disclosure read.

Renata was founded in 1972 as Pfizer Laboratories (Bangladesh) and has since grown to become a major player in the domestic and international markets. 

Along with its subsidiaries in United Kingdom and in Ireland, the group is now exporting to 50 countries across the world.

Notably, Renata is among the few companies supplying this strength in the UK market, underscoring its commitment to expanding access to high-quality endocrine therapies and bolstering its growing presence in global regulated markets.

In the last 2024-25 fiscal, Renata reported a consolidated revenue of Tk4,248 crore, and profit of Tk222 crore.

Renata earned Tk217.84 crore from exports, which is up from Tk190.97 crore in the previous fiscal year. 

Renata (UK), subsidiary of Renata reported Tk1.49 crore revenue, while Renata Pharmaceuticals (Ireland) reported Tk38.93 crore revenue, which was Tk82 lakh and Tk20 crore respectively in FY24.